Bostarelboston 20

Bostarelboston 20

201912-0051 • 7540 Views • Box of 2 blisters x 30 film-coated tablets
COMPOSITION

Each film coated tablet contains:

Active ingredient:

Trimetazidine HCl 20 mg

 

Trimetazidine is indicated in combination for the symptomatic treatment of adult patients with stable angina pectoris (angina) that is insufficiently controlled, or presenting intolerance to first-line antianginal treatments

POSOLOGY AND METHOD OF ADMINISTRATION

Method of administration: Oral route, take with meals

Posology

One tablet of trimetazidine 20 mg, three times a day

Special populations:

+ Kidney failure: The recommended dose in patients with moderate renal impairment (creatinine clearance [30 - 60 ml/min]), is one 20 mg tablet twice daily, i.. e. one tablet in the morning and one in the evening, at mealtimes.

+ Elderly subjects: An increase in trimetazidine exposure, due to age-related renal impairment, may occur in the elderly. In patients with moderate renal impairment (Creatinine clearance [30 - 60 ml/min]), the recommended dose is one 20 mg tablet twice daily, i.e. one tablet in the morning and one in the evening, at mealtimes. In the elderly, dose adjustments should be made with caution.

+ Pediatric population: The safety and effectiveness of trimetazidine in children under 18 years of age have not been established. No data is available

CONTRAINDICATIONS

Hypersensitivity to trimetazidine or to any of the excipients.

Parkinson's disease, parkinsonian symptoms, tremors, restless leg syndrome and other related motor abnormalities.

Severe renal impairment (creatinine clearance < 30 ml/min).

WARNINGS AND PRECAUTIONS

Trimetazidine can induce or aggravate parkinsonian symptoms (tremor, akinesia, hypertonia), which must be regularly sought, especially in the elderly. If in doubt, patients should be referred to a neurologist for appropriate examinations.

The occurrence of movement disorders such as parkinsonian symptoms, restless legs syndrome, tremors, postural instability, should lead to definitive discontinuation of trimetazidine.

The incidence of these cases is low and they are usually reversible upon discontinuation of treatment. The majority of patients recover within 4 months of stopping trimetazidine. If parkinsonian symptoms persist for more than 4 months after stopping treatment, the advice of a neurologist should be sought.

Falls may occur in connection with postural instability or hypotension, particularly in patients on antihypertensive therapy (see section 4.8).

Trimetazidine should be prescribed with caution in patients for whom increased exposure is expected: moderate renal impairment, subjects aged over 75 years

SHELF-LIFE

36 months from the manufacturing date. Do not use after the expiry date

 

Box of 2 blisters x 30 film-coated tablets.

Your comment
19001910
Confirm information
Please confirm that you are a pharmacist, doctor, medical specialist,... and want to learn about the product. The information described here is only to help readers better understand the product, not for advertising or treatment purposes.